Insulet jumps after Q4 EPS and revenue beat, margin expansion and record Omnipod growth power a strong 2025 finish and upbeat ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2025 results exceeding the market’s revenue ...

Its Q4 revenue jumped ~29% YoY on a constant currency basis to $783.8M, exceeding the consensus by $15.1M, as its revenue from its Omnipod insulin pump rose ~28% YoY and ~42% YoY in the U.S. and ...

Insulet Corporation PODD stock is trading higher on Wednesday after the company reported better-than-expected fourth-quarter ...

According to TipRanks.com, Wood is a 1-star analyst with an average return of -1.2% and a 47.2% success rate. Wood covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies ...

Feb 18 (Reuters) - Insulet reported better-than-expected fourth-quarter results on Wednesday, on the back of strong demand for its tubeless insulin pumps that eliminate the need for daily injections.

According to TipRanks, Newitter is a 5-star analyst with an average return of 10.0% and a 49.59% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems ...

For the quarter ended December 2025, Insulet (PODD) reported revenue of $783.8 million, up 31.2% over the same period last year. EPS came in at $1.55, compared to $1.15 in the year-ago quarter. The ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...